Bandhan Mutual Fund picks up a small stake in Viyash Scientific
Bandhan Mutual Fund picked up a small stake in Viyash Scientific — just 28 shares at ₹263.0, dated August 26, 2026, confirmed in exchange bulk-deal data. It's a tiny position size, but the company behind it has a genuinely interesting turnaround story.
CMP ₹248 (as of Sept 21, 2026) · Market cap ~₹10,938 crore · P/E ~57.9x (vs. Laurus Labs' ~121x, a larger listed API/CDMO peer — the comparison is rough since Viyash's business mix is different, split across animal health, US generics, and API manufacturing)
What Viyash Scientific actually does
Viyash Scientific was formerly known as Sequent Scientific — the name changed after Sequent merged with Viyash Life Sciences. It runs three distinct businesses: animal medicines (its largest, sold across Europe, Turkey, Brazil, Mexico, and India), human generic medicines sold only in the US through a subsidiary called Appco, and a contract-manufacturing business making Active Pharmaceutical Ingredients (APIs — the raw chemical building blocks of drugs) both for itself and for large global pharma companies that outsource this work.
Management describes the Sequent-Viyash merger integration as "now complete... one of the few successful integrations you can find in the industry." The company is now building toward specialised cancer-drug ingredients, though commercial revenue from that pipeline isn't expected until 2029.
Q1 FY27: real margin expansion, with real one-time noise in the profit number
Revenue grew 19.5% YoY to ₹946 crore. The more important number: EBITDA margin expanded sharply, from 16.2% to 21.6% — a 530 basis-point jump in a single year.
Metric Q1 FY27 Q1 FY26 Change ------------ Revenue ₹946 Cr — +19.5% Gross margin 54.1% 51.9% +220 bps EBITDA margin 21.6% 16.2% +530 bps PAT ₹79 Cr ₹37 Cr +115% Net debt/EBITDA 0.1x ~1x (a year ago) Sharp deleveraging
PAT more than doubled — but even that headline number understates the underlying improvement, because it's after absorbing a one-time ₹19 crore ESOP charge tied to the merger. Two structural tailwinds are also still working through the numbers: finance costs fell from ₹20.4 crore to ₹12.5 crore as debt came down, and goodwill amortisation (₹25 crore this quarter) is guided to fall to near-zero by Q3 FY27 — adding roughly ₹15 crore of extra profit per quarter from then on, with nothing else needing to change.
Why reported profit looks smaller than the real improvement A large, temporary ESOP charge (~₹150 crore across FY27) and a shrinking goodwill amortisation bill mean this year's headline PAT is a poor measure of the company's actual, sustainably higher earnings power — that shows up more clearly starting FY28.
The part that actually turned around: the US business
The US generics business (Appco) was restructured — volume products moved to India-based manufacturing, backed by the company's own API supply — and its EBITDA margin jumped from roughly 1% to 34-35%. When an analyst asked directly whether that's sustainable, management didn't hedge: "we are expecting this will continue." The company holds 50-55% market share in its key US products.
A European acquisition, and management's own reckoning with a past failure
Viyash has signed an agreement to acquire BioForLife in Italy — 85 companion-animal products and 85% vet-clinic coverage there — expected to close within 2-3 months of the call. What's genuinely notable: an analyst directly challenged this given Sequent's own earlier European acquisition (Alivira) was a costly, difficult experience, and India's pharma sector broadly has a poor record with European M&A. Management didn't deflect — it acknowledged the past failures candidly ("we can't Indianize Europe operations") and described BioForLife specifically as a no-manufacturing, brand-and-distribution "launch pad" rather than a repeat of the earlier mistake.
Management's guidance
Per the Q1 FY27 concall:
- FY27 revenue: ~₹4,000 crore (management's internal working assumption) - EBITDA margin: sustained in the 20-22% band (Q1 already delivered 21.6%) - Long-term target: $1 billion revenue by roughly FY32 — management said this works out to an 18% CAGR from FY27, calling it "realistic and practical, not just ambitious." That math holds up: FY27's ~₹4,000 crore base, compounding at 18% for five years, lands at roughly ₹9,100-9,200 crore — which converts to about $955-965 million at ₹95-96/$ (the current exchange rate), consistent with management's stated "$1 billion" - Companion animal sub-segment: targeted at $150-200 million by FY32 - Oncology API revenue: not expected before FY29, given long development and patent timelines
These are management's own forward-looking statements, not guaranteed outcomes.
Risks worth flagging
- Europe growth was flat in local-currency terms this quarter (EUR 16.8 million, unchanged YoY) — an analyst pressed on this directly, and management didn't dispute the flat figure, instead pointing to full-year INR guidance that depends partly on currency tailwinds and H2 seasonality - The ESOP charge is large and lumpy — ~₹150 crore across FY27, front-loaded in Q2-Q4, meaning reported PAT stays a weak proxy for real operating performance until FY28 - BioForLife integration risk — explicitly flagged by an analyst given the company's own prior European acquisition problems - Long payback period — new oncology API and formulation revenue is 3-5+ years out, meaning capital is being committed well ahead of any return - Minority interest — roughly 16-17% of profit currently leaks to minority shareholders in partially-owned US and Spain subsidiaries; a buyout is planned within 1-2 years but timing isn't firm
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://upstox.com/stocks/viyash-scientific-limited-share-price/ - https://www.screener.in/company/LAURUSLABS/consolidated/